Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2259970 | 0.87 | HDAC1 (0.44) | HDAC1TAAR1HDAC3HDAC2NCOR2 | |
| SCHEMBL16468452 | 0.85 | AOC3 (0.44) | RIPK1AOC3HDAC1TAAR1CTSL | |
| SCHEMBL2258715 | 0.84 | HDAC3 (0.43) | CARM1PRMT1HDAC1HDAC3HDAC2 | |
| SCHEMBL1231760 | 0.84 | HDAC3 (0.53) | CARM1HDAC1CTSLRECQLHDAC3 | |
| SCHEMBL2260867 | 0.84 | CARM1 (0.42) | CARM1PRMT1HDAC1TAAR1TSHR | |
| SCHEMBL2535059 | 0.83 | TAAR1 (0.44) | RIPK1AOC3HDAC1TAAR1HDAC3 | |
| SCHEMBL2257957 | 0.83 | TAAR1 (0.46) | TAAR1 | |
| SCHEMBL21987970 | 0.82 | RIPK1 (0.51) | RIPK1AOC3CTSLTSHRRECQL | |
| SCHEMBL19208209 | 0.81 | TSHR (0.48) | RIPK1HDAC1CTSLTSHRRECQL | |
| SCHEMBL2263360 | 0.80 | IDO1 (0.42) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994326-B2 | For treatment of various forms of neurodegeneration, including that from stroke, Alzheimer's disease, Parkinson's disease, and Huntington's disease | NORTHWESTERN UNIVERSITY (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994326-B2 | For treatment of various forms of neurodegeneration, including that from stroke, Alzheimer's disease, Parkinson's disease, and Huntington's disease | NORTHWESTERN UNIVERSITY (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994326-B2 | For treatment of various forms of neurodegeneration, including that from stroke, Alzheimer's disease, Parkinson's disease, and Huntington's disease | NORTHWESTERN UNIVERSITY (US) | 2011-08-09 | — | — | US | disclosed |
| US-20080108814-A1 | Potent and highly selective heteroaromatic inhibitors of neuronal nitric oxide synthase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-05-08 | — | — | US | disclosed |
| US-20080108814-A1 | Potent and highly selective heteroaromatic inhibitors of neuronal nitric oxide synthase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-05-08 | — | — | US | disclosed |
| US-20080108814-A1 | Potent and highly selective heteroaromatic inhibitors of neuronal nitric oxide synthase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-05-08 | — | — | US | disclosed |
| WO-2008042353-A1 | POTENT AND HIGHLY SELECTIVE HETEROAROMATIC INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE | NORTHWESTERN UNIVERSITY (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108814-A1 | Potent and highly selective heteroaromatic inhibitors of neuronal nitric oxide synthase | NOS1, NOS2, NOS3 | RIPK1 2910/4885CARM1 859/4885PRMT1 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.